文献速递淋巴瘤

正电子发射断层扫描导向治疗用于局限期弥漫性大B细胞淋巴瘤患者:组间国家临床试验网络S1001研究结果

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
PubMed 文献 · J Clin Oncol · 2020-07-13

S1001研究为美国前瞻性研究,入组非巨块型I/II期初治弥漫性大B细胞淋巴瘤患者,接受3周期R-CHOP后行中期PET/CT,阴性者继续1周期R-CHOP,阳性者接受累及野放疗后行替伊莫单抗放射免疫治疗。158例入组、132例合格、128例行iPET,14例(11%)阳性;中位随访4.92年,5年无进展生存估计87%(95%CI 79%–92%),总生存估计89%(95%CI 82%–94%),iPET阳性与阴性患者结局相似。

要点

  • 非巨块型I/II期DLBCL接受3周期R-CHOP后行iPET,阴性者加1周期R-CHOP。
  • 128例行iPET者中14例(11%)阳性,阳性者接受累及野放疗后替伊莫单抗放射免疫治疗。
  • 5年无进展生存估计87%(95%CI 79%–92%),总生存估计89%(95%CI 82%–94%)。

核心结论

  • S1001是作者所知美国在利妥昔单抗时代最大的局限期DLBCL前瞻性研究,取得该疾病亚组NCTN最佳结果。
  • PET导向治疗下89%的iPET阴性患者接受4周期R-CHOP,仅11%的iPET阳性患者需要放疗,两组结局均极佳。
  • 该试验确立单用4周期R-CHOP作为绝对多数局限期患者的新标准方案。

研究设计与样本

  • 美国国家临床试验网络(NCTN)前瞻性研究,入组非巨块型(<10 cm)I/II期初治DLBCL患者。
  • 患者接受3周期标准R-CHOP后行中心复核的中期PET/CT(iPET)。
  • iPET阴性者继续1周期R-CHOP,iPET阳性者接受累及野放疗后行替伊莫单抗放射免疫治疗。
  • 158例入组,132例合格,128例行iPET。

主要发现

  • 128例行iPET者中14例(11%)为阳性。
  • 中位随访4.92年(范围1.1–7.7年),仅6例进展,3例死于淋巴瘤。
  • 11例死于非淋巴瘤原因,中位年龄80岁。
  • 5年无进展生存估计为87%(95%CI 79%–92%),总生存估计为89%(95%CI 82%–94%)。
  • iPET阳性与iPET阴性患者结局相似。

关键数值与推荐

  • 非巨块型定义为<10 cm。
  • iPET阴性者接受R-CHOP共4周期,iPET阳性者接受累及野放疗后替伊莫单抗放射免疫治疗。

临床怎么用

  • 作者认为该试验确立单用4周期R-CHOP作为绝对多数局限期DLBCL患者的新标准方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in 25% to 30% of patients, with better overall survival (OS) than that for advanced-stage disease but with continuous relapse regardless of treatment approach. The preferred treatment is abbreviated rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and radiation therapy. On the basis of promising results of positron emission tomography (PET)-directed treatment approaches, we designed a National Clinical Trials Network (NCTN) study to improve outcomes and decrease toxicity. METHODS: Patients with nonbulky (< 10 cm) stage I/II untreated DLBCL received 3 cycles of standard R-CHOP therapy and underwent a centrally reviewed interim PET/computed tomography scan (iPET). Those with a negative iPET proceeded with 1 additional cycle of R-CHOP, whereas those with a positive iPET received involved field radiation therapy followed by ibritumomab tiuxetan radioimmunotherapy. RESULTS: Of 158 patients enrolled, 132 were eligible and 128 underwent iPET, which was positive in 14 (11%) of the patients. With a median follow-up of 4.92 years (range, 1.1-7.7 years), only 6 patients progressed and 3 died as a result of lymphoma. Eleven patients died as a result of nonlymphoma causes at a median age of 80 years. The 5-year progression-free survival estimate was 87% (95% CI, 79% to 92%) and the OS estimate was 89% (95% CI, 82% to 94%), with iPET-positive and iPET-negative patients having similar outcomes. CONCLUSION: To our knowledge, S1001 is the largest prospective study in the United States of limited-stage DLBCL in the rituximab era, with the best NCTN results in this disease subset. With PET-directed therapy, 89% of the patients with a negative iPET received R-CHOP × 4, and only 11% had a positive iPET and required radiation, with both groups having excellent outcomes. The trial establishes R-CHOP × 4 alone as the new standard approach to limited-stage disease for the absolute majority of patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Persky DO, Li H, Stephens DM, et al. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020. PMID: 32658627. doi:10.1200/JCO.20.00999

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。